Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11545| Title: | Hypocalcemia induced by raloxifene. | Austin Authors: | Vu, Thuy D T;Varadarajan, Suresh;Seeman, Ego ;Jerums, George ;MacIsaac, Richard J | Affiliation: | Endocrinology Department, Austin Health, Victoria, Australia | Issue Date: | 1-Apr-2012 | Publication information: | Current Drug Safety; 7(2): 176-8 | Abstract: | Raloxifene is an anti-resorptive agent used in postmenopausal osteoporosis. This is the first report of the occurrence of clinically significant hypocalcemia following raloxifene treatment in a patient with occult vitamin D deficiency. Since vitamin D deficiency is widely prevalent in the community, screening for vitamin D deficiency and its correction is advisable before the initiation of anti-resorptive therapy. | Gov't Doc #: | 22873502 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/11545 | Journal: | Current drug safety | URL: | https://pubmed.ncbi.nlm.nih.gov/22873502 | Type: | Journal Article | Subjects: | Aged, 80 and over Bone Density Conservation Agents.adverse effects.therapeutic use Female Humans Hypocalcemia.chemically induced Mass Screening.methods Osteoporosis, Postmenopausal.drug therapy Raloxifene.adverse effects.therapeutic use Vitamin D Deficiency.complications.diagnosis |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.